Ernexa Therapeutics (NASDAQ:ERNA) Shares to Reverse Split on Monday, May 4th

Posted by Jeff Wilder on Apr 30th, 2026

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report)’s stock is set to reverse split before the market opens on Monday, May 4th. The 1-25 reverse split was announced on Thursday, April 30th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, May 1st.

Ernexa Therapeutics Stock Down 21.2%

Shares of NASDAQ:ERNA traded down $0.04 during trading on Thursday, hitting $0.15. 2,009,922 shares of the company were exchanged, compared to its average volume of 578,476. Ernexa Therapeutics has a 12-month low of $0.13 and a 12-month high of $4.02. The firm’s 50 day moving average price is $0.24 and its 200-day moving average price is $0.87.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.01) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Check Out Our Latest Stock Report on ERNA

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 70.55% of the stock is owned by institutional investors.

Ernexa Therapeutics Company Profile

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.